27
TORRENT PHARMACEUTICALS LTD. Business Statistics and Quantitative Technique Submission to : Mr. Tafheem Submission by : Sushain Mahajan MBA (PM), 2 nd Semester

Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

Embed Size (px)

Citation preview

Page 1: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

TORRENT PHARMACEUTICALS LTD.

Business Statistics and Quantitative TechniqueSubmission to : Mr. Tafheem

Submission by : Sushain Mahajan MBA (PM), 2nd Semester

Page 2: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

INDEX Introduction. History. Mission , Vision and Values. List of API’s Manufactured. Analysis of Profits with specific

calculations using business statistics.

Page 3: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

INTRODUCTION OF COMPANY: Torrent Pharma is in the Pharmaceuticals sector. Torrent Pharmaceuticals Ltd. is the flagship company of

the Torrent Group. Based in Ahmedabad , it was promoted by U. N. Mehta

initially as Trinity Laboratories Ltd. and was later renamed to its current name Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals operates in more than 50 countries with over 1000 product registrations globally.

The current market capitalisation stands at Rs 21,510.75 crore.

Page 4: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

COMPANY MANAGEMENT INCLUDES:

• Ashish Nanda,

• Bhavna Doshi

• Samir Mehra

• Markand Bhatt,

• Pradeep Bhargava,

• Shailesh Haribhakti 

• Sudhir Mehta

Chairman

Director

Independent

DirectorExecutive Vice

Chairman

Page 5: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

HISTORY: 1972 - The Company was incorporated on 15th July, as a Private

Limited Company by Shri Rajnikant C. Patel and his family members, and in June 1982, the company was acquired by Shri Uttamlal N. Mehta.

1989 - On 28th June the Company became a deemed Public Company under the provisions of Section 43-A of the Act and by a Special Resolution passed on 25th July, 1992 at the Annual General Meeting, the Company became a Public Limited Company within the meaning of Section 3(1)(iv) of the act and adopted a new set of articles.

1992 - Torrent Laboratories Limited, was amalgamated with the Company with effect from 1st April by an order of the Honourable High Court of Gujarat, dated 22nd December.

1993 - The Company proposes to modernize its present manufacturing facilities located at Vatva and Chhatral to conform to the GMP requirements as also to incorporate the latest technology available in the field.

Page 6: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

During the year, Torrent Medi-Systems Limited (TMSL) was merged with the Company with effect from 1st April consequent to the scheme of amalgamation approved by the Honourable High Court of Gujarat.

1994 - The Company issued 1,74,144 Equity Shares of Rs.10 each as fully paid up shares to the shareholders of TMSL after cancelling 9,300 Shares held by the Company in TMSL.

The Company was the first to launch ranitidine (Ranitin), nifedipine (Calcigard,) atenolol (Betacard), domperidone (Domstal), diltiazem (Dilzem), amiodorane (Cordarone), Lisinopril (Listril), etc. in the Indian market.

During the year the Company launched a number of new products like Zirtin, Tyklid, Flutamide and Topcef, all of which were well received in the market place.

1995 - During the year the Company launched a number of new products like Lomef (Lomefloxacin), Dilzem Inj. (Diltiazem), Depidol LA (Haliiperidiil Decanoate) Oncoden (Ondancetron), Nimotide (Nimodipne), Pefcin (Pefloxacin) which have gained wide acceptance in the pharmaceutical market.

Page 7: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

1999 - Among the new products launched recently included Nikoran IV for critical care in cardiology and a novel drug approved for launch in the anti-epileptic category.

2002 - Torrent Pharma’s manufacturing facilities certified with ISO 14001:1996.

Torrent’s R&D Centre received ISO/IEC 17025:1999 for its facilities by National Accreditation Board for Testing and Calibration Laboratories (NABL).

2003 - Torrent Pharma sets up a wholly owned subsidiaries in Germany and Brazil.

2004 - Torrent Pharmaceuticals Limited (TPL) has signed a non-exclusive agreement with Dr. Reddy's Laboratories Limited (DRL) for licensing and supplying the formulation of one of Torrent's blockbuster drug 'Domstal O' in the Gastro Intestinal segment

Page 8: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

2005 - Torrent Pharmaceuticals signs agreement with Novo Nordisk, Denmark to establish new, dedicated formulation and packaging facility for Insulin, exclusively for Novo Nordisk.

2006 - Torrent Pharma Receives USFDA Approval. Torrent’s Azuca launches 2 new blockbusters, Pregeb and Piopod.

2010 - The Board has recommended a dividend of Rs. 6.00 per equity share having face value of Rs. 5/- each.

2012 - The Board has appointed Haigreve khaitan as Additional Director.

The Board has recommended a final dividend of Rs. 2.50 per equity share.

Page 9: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

MISSION, VISION AND VALUES OF TORRENT PHARMACEUTICALS LTD.

• We commit ourselves to total customer care by delivering world-class products and services.

Mission

• To be the leader in the pharmaceutical industry.Vision

Page 10: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

• A set of core value continue to guide us through the process of transforming the conglomerate into a high-performing and caring organization for our customers, employees, shareholders and society.

• Improving quality of life of our customers, as we believe quality is a way of life.• Creating value for our

shareholders, for the trust bestowed on us.

• Building an empowered and ethical Torrent family, as the foundation for a bright future.

• Responsibility towards the society and environment, as we owe our existence to them.

• Striving for excellence in whatever we do, to follow the exclusive path to leadership.

• Flexibility and speed shall be our oars for navigating the turbulent .

Values

Page 11: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx
Page 12: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

Risperidone

Venlafaxine

Hydrochloride

Nicorandil

Sertraline

Hydrochloride

Lamotrigine

Nebivolol

Hydrochloride

API’S MANUFACTURED

Page 13: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

Ormeloxifen

Hydrochloride

Ropinarole

Hydrochloride

Duloxetine

Hydrochloride

API’S MANUFACTURED

Page 14: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

ANALYSIS OF PROFITS:Following Financial Reports are used for

the analysis of profits of Torrent Pharmaceuticals Ltd.

Quarter Ended June

2013

Quarter Ended

September 2013

Quarter Ended

December 2013

Quarter Ended

March 2014

Quarter Ended June

2014

Quarter Ended

September 2014

Quarter Ended

December 2014

Page 15: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

• Profit : Rs. 149 crores

Quarter Ended June 2013

• Profit : Rs. 113 crores

Quarter Ended September 2013

• Profit : Rs. 158 crores

Quarter Ended December 2013

Page 16: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

• Profit : Rs. 224 crores

Quarter Ended March 2014

• Profit : Rs. 256 crores

Quarter Ended June 2014

• Profit : Rs. 198 crores

Quarter Ended September 2014

• Profit : Rs. 167 crores

Quarter Ended December 2014

Page 17: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

MEASURES OF CENTRAL TENDENCIES: A measure of central tendency is a single value that attempts

to describe a set of data by identifying the central position within that set of data.

As such, measures of central tendency are sometimes called measures of central location.

They are also classed as summary statistics.

The mean (often called the average) is most likely the measure of central tendency that you are most familiar with, but there are others, such as the median and the mode.

Page 18: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

• The mean is equal to the sum of all the values in the data set divided by the number of values in the data set.

Mean:

• total no. of sample and ‘X’ correspond to the observed valued.

Formula of mean is:

Page 19: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

• The median is the middle score for a set of data.

• When there is an odd number of numbers, the median is simply the middle number.

Median:

• Where ‘n’ is the number of samples

Formula of Median is:

Page 20: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

• Mode of a set of data is the number with the highest frequency.

Mode:

• A statistic used as a measure of the dispersion or variation in a distribution or set of data, equal to the square root of the arithmetic mean of the squares of the deviations from the arithmetic mean.

Standard Deviation:

Page 21: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

Formula of Standard Deviation is:

Page 22: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

• => 149+113+158+224+256+198+167

• 7• => 1265• 7• => 180.71

Therefore, the mean profit of Torrent Pharmaceuticals Ltd. in 7 quarters is Rs. 180.71 crores.

• Profit : Rs. 149 crores

Quarter Ended June 2013

• Profit : Rs. 113 crores

Quarter Ended September 2013

• Profit : Rs. 158 crores

Quarter Ended December 2013

• Profit : Rs. 224 crores

Quarter Ended March 2014

• Profit : Rs. 256 crores

Quarter Ended June 2014

• Profit : Rs. 198 crores

Quarter Ended September 2014

• Profit : Rs. 167 crores

Quarter Ended December 2014

Page 23: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

• Data in ascending order : 113,149,158,167,198,224,256

• [(n+1)/2]th data

• [ (7+1)/2]th = 4th

observation

• 167 (Rs. in crores)Therefore, the Median is Rs. 167 crores.

• Profit : Rs. 149 crores

Quarter Ended June 2013

• Profit : Rs. 113 crores

Quarter Ended September 2013

• Profit : Rs. 158 crores

Quarter Ended December 2013

• Profit : Rs. 224 crores

Quarter Ended March 2014

• Profit : Rs. 256 crores

Quarter Ended June 2014

• Profit : Rs. 198 crores

Quarter Ended September 2014

• Profit : Rs. 167 crores

Quarter Ended December 2014

Page 24: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

• The mode of a set of data is the number with highest frequency, here there is no repetition.

Therefore, there is no Mode.

• Profit : Rs. 149 crores

Quarter Ended June 2013

• Profit : Rs. 113 crores

Quarter Ended September 2013

• Profit : Rs. 158 crores

Quarter Ended December 2013

• Profit : Rs. 224 crores

Quarter Ended March 2014

• Profit : Rs. 256 crores

Quarter Ended June 2014

• Profit : Rs. 198 crores

Quarter Ended September 2014

• Profit : Rs. 167 crores

Quarter Ended December 2014

Page 25: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

Therefore, the standard deviation is Rs. 48.53 crores.

• Profit : Rs. 149 crores

Quarter Ended June 2013

• Profit : Rs. 113 crores

Quarter Ended September 2013

• Profit : Rs. 158 crores

Quarter Ended December 2013

• Profit : Rs. 224 crores

Quarter Ended March 2014

• Profit : Rs. 256 crores

Quarter Ended June 2014

• Profit : Rs. 198 crores

Quarter Ended September 2014

• Profit : Rs. 167 crores

Quarter Ended December 2014

Page 26: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

BUSINESS IMPLICATION: Torrent Pharmaceuticals Ltd. have

average of Rs. 180.71 crores of profit after the calculation.

Torrent Pharmaceuticals Ltd. highest profits has been Rs. 256 crores while lowest profit has been Rs. 113 crores.

Page 27: Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx

THANK YOU

Reference:

http://www.torrentpharma.com